Definium Therapeutics' LSD-Based Psych Drug Scores Again | Investor's Business DailySectionsMy IBDMy ProductsRecently SearchedTechnologyLicensingALLISON GATLIN09:24 AM ET 08/12/2026Definium Therapeutics (DFTX) unveiled the second of two positive Phase 3 studies for its LSD-based drug. The biotech stock surged on the results. Patients with generalized anxiety disorder, or GAD, showed a 5.4-point improvement compared with a placebo on the 56-point Hamilton Anxiety Rating Scale. That beat the 4-point improvement investors had been hoping to see, RBC Capital Markets analyst…Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8INVESTING RESOURCESTake a Trial TodayGet instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!IBD VideosGet market updates, educational videos, webinars, and stock analysis.Get StartedLearn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content. ]]>